Floatz logo

Amg 162

Bone Metastases in Subjects With Advanced Breast Cancer

AmgenPhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Bone Metastases in Subjects With Advanced Breast Cancer cohort.

Asset / SponsorPhaseRating
Denosumab
Amgen
Phase 3BB

Same molecule, other indications

Amg 162 is also rated in:

OsteopeniaDormant
BB
Indicative ·
64 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
52 / 100
View asset →
prostate cancerDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →